Chao Chen

Ms. Chao Chen

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2024 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
WSWei Shi
Wei Shi
Zheng ChenZheng Chen
Zheng Chen
LSLiping Shi
Liping Shi
SJSiyuan Jiang
Siyuan Jiang
JZJianguo Zhou
Jianguo Zhou
JTJoseph Ting
Joseph Ting
Early-onset sepsis (EOS) poses a substantial risk to very preterm infants, necessitating the prevalent administration of empirical antibiotics in the neonatal intensive care unit (NICU). Puopolo et al1 reported that more than one-third of the extremely preterm infants in their study were categorized as low risk for EOS, with an incidence of 0.5%. In these low-risk groups, prolonged empirical antibiotic treatment (≥5 days) was observed in approximately 35% of cases.1 Recent studies1-3 have suggested a potential association of prolonged antibiotic therapy with both increased mortality and a higher incidence of adverse neonatal outcomes, including bronchopulmonary dysplasia (BPD), within this vulnerable population. However, these studies often relegated BPD as a secondary outcome, lacking comprehensive consideration of relevant confounding factors. Moreover, the literature has reported inconsistent results in this domain.4-6 The reported association may be influenced by factors such as culture-proven sepsis bacteremia, illness severity, and early respiratory disease.

16 January 2025 in Nanomaterials
Verified
Journal Article
Open access
PDF file
CCChao Chen
Chao Chen
越许越 许
越 许
HMHui Meng
Hui Meng
HBHongyi Bao
Hongyi Bao
Yong HuYong Hu
Yong Hu
DXDonglin Xia
Donglin Xia
Nano-oncologic vaccines represent a groundbreaking approach in the field of cancer immunotherapy, leveraging the unique advantages of nanotechnology to enhance the effectiveness and specificity of cancer treatments. These vaccines utilize nanoscale carriers to deliver tumor-associated antigens and immunostimulatory adjuvants, facilitating targeted immune activation and promoting robust antitumor responses. By improving antigen presentation and localizing immune activation within the tumor microenvironment, nano-oncologic vaccines can significantly increase the efficacy of cancer immunotherapy, particularly when combined with other treatment modalities. This review highlights the mechanisms through which nano-oncologic vaccines operate, their potential to overcome existing limitations in cancer treatment, and ongoing advancements in design. Additionally, it discusses the targeted delivery approach, such as EPR effects, pH response, ultrasonic response, and magnetic response. The combination therapy effects with photothermal therapy, radiotherapy, or immune checkpoint inhibitors are also discussed. Overall, nano-oncologic vaccines hold great promise for changing the landscape of cancer treatment and advancing personalized medicine, paving the way for more effective therapeutic strategies tailored to individual patient needs.

1 June 2014
Verified
Conference Paper
Closed access
CCChao Chen
Chao Chen
YHYining Huang
Yining Huang
YLYi Liu
Yi Liu
CLChengdong Liu
Chengdong Liu
LMLingchao Meng
Lingchao Meng
BJBingli Jiao
Bingli Jiao
Adverse Drug Reactions (ADRs) has become a worldwide problem that draws the attention of people from all racial and ethnic groups. The number of deaths caused by ADRs has greatly increased and led to many drug withdrawals in the last decades. Recent research findings indicate that most ADRs can be effectively prevented to some extent by using computer-aided information technologies. Though many spontaneous reporting systems (SRSs) have been built to enhance the pharma-covigilance, the ADRs data is still very sparse because the large amount of reports obtained from consumers contains insufficient hints to identify a possible causal relationship between an adverse event and drug. Based on this motivation, we developed Adverse-Tracking, a spontaneous reporting system of ADRs via crowd-sourcing. Our proposed system interacts with consumers through a Q&A interface and collects the ADR reports. The decision tree support vector machine (DTSVM) based on the genetic algorithm is used in our system to automate the Q&A procedure. We carried out experiments to evaluate the performance at Peking University First Hospital. As demonstrated by the results, our system is an efficient tool to track and discover adverse events in the consumers' reports of ADRs, which facilitates the detection of “signal”.

5 July 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HHHao Huang
Hao Huang
XWXiaoping Wang
Xiaoping Wang
ZGZiqing Gao
Ziqing Gao
HBHongyi Bao
Hongyi Bao
XYXiaopeng Yuan
Xiaopeng Yuan
XWXiangqian Wang
Xiangqian Wang
Optimizing the delivery and penetration of nano-sized drugs within liver cancer sites, along with remodeling the tumor microenvironment, is crucial for enhancing the efficacy of chemotherapeutic agents. For this study, a platelet (PLT)-mediated nanodrug delivery system (DASA+ATO@PLT) was developed to improve the effectiveness of chemotherapy. This system delivers nano-sized dasatinib and atovaquone specifically to liver tumor sites and facilitates intra-tumoral permeation upon release. Through JC-1, immunohistochemistry, and DNA damage analyses, the therapeutic effect of DASA+ATO@PLT was assessed. In vitro simulation and intravital imaging were carried out to determine the accumulation of dasatinib and atovaquone in liver tumor sites. The experiment demonstrated the accumulation of dasatinib and atovaquone in tumor sites, followed by deep permeation in the tumor microenvironment with the assistance of PLTs, while simultaneously revealing the ability of DASA+ATO@PLT to remodel the liver cancer microenvironment (overcoming hypoxia) and enhance chemotherapeutic efficacy. This system utilizes the natural tumor recognition ability of PLTs and enhances the chemo-immunotherapeutic effect through targeted delivery of nano-chemotherapeutic drugs to the tumor, resulting in effective accumulation and infiltration. The PLT-mediated nanodrug delivery system serves as a “Trojan horse” to carry therapeutic drugs as cargo and deliver them to target cells, leading to favorable outcomes.

1 October 2019 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
YMYang Mi
Yang Mi
XLXiufeng Liu
Xiufeng Liu
CZCheng Zhang
Cheng Zhang
FLFeng Liao
Feng Liao
ZLZixiong Li
Zixiong Li
CCChao Chen
Chao Chen
Objectives: Despite recent advances in the treatment of advanced ovarian cancer, drug selection after second-line chemotherapy has not been well studied. In this study, we retrospectively evaluated the effect and safety of apatinib as monotherapy or in combination with chemotherapy for the treatment of advanced ovarian cancer after second-line treatment. Methods: We reviewed the medical records of patients from April 2016 to October 2018 with advanced ovarian cancer who received apatinib after failed second-line chemotherapy. Overall survival (OS) and progression-free survival (PFS) were calculated by the Kaplan–Meier method. Response rate (RR) and disease control rate (DCR) were evaluated using radiologic reports according to RECIST 1.1 criteria. Treatment-related adverse events were evaluated based on NCI-CTC version 4.0. Results: Study concerned 22 evaluated cases; of them, 13 patients received apatinib combined with chemotherapy and 9 patients received apatinib monotherapy. The median PFS was 8.2 months (9.7 months in combined group and 4.4 months in monotherapy group, P value was 0.21). The median OS was 13.1 months (13.6 months in combined group and 11.6 months in monotherapy group, P value was 0.45). The RR was 20% and DCR was 85% (combined group: RR 33.3%, DCR 100%, monotherapy group: RR 0%, DCR 62.5%). The main side effect was hypertension (9/22), proteinuria (7/22), oral mucositis (5/22), hand and foot syndrome (6/22%), leukopenia (5/22), etc. Conclusion: Apatinib showed good efficacy and safety for advanced ovarian cancer patients whether used alone or in combination with chemotherapy. In the meanwhile, this study is limited by the small cases number. Therefore, further research is needed to provide more data and ultimately apply it to guide clinical practice.

11 October 2022 in Nanomaterials
Verified
Journal Article
Open access
PDF file
LFLingzi Feng
Lingzi Feng
XHXinzhong Huang
Xinzhong Huang
JLJia Li
Jia Li
CCChao Chen
Chao Chen
YMYidan Ma
Yidan Ma
DXDonglin Xia
Donglin Xia
Failure to control blood glucose level (BGL) may aggravate oxidative stress and contribute to the development of diabetic nephropathy (DN). Using erythrocytes (ERs) as the carriers, a smart self-regulatory insulin (INS) release system was constructed to release INS according to changes in BGLs to improve patients’ compliance and health. To overcome the limited sources of ERs and decrease the risk of transmitting infections, we developed an in vitro, closed-loop autologous ER-mediated delivery (CAER) platform, based on a commercial hemodialysis instrument modified with a glucose-responsive ER-based INS delivery system (GOx-INS@ER). After the blood was drained via a jugular vein cannula, some of the blood was pumped into the CAER platform. The INS was packed inside the autologous ERs in the INS reactor, and then their surface was modified with glucose oxidase (GOx), which acts as a glucose-activated switch. In vivo, the CAER platform showed that the BGL responsively controlled INS release in order to control hyperglycemia and maintain the BGL in the normal range for up to 3 days; plus, there was good glycemic control without the added burden of hemodialysis in DN rabbits. These results demonstrate that this closed-loop extracorporeal hemodialysis platform provides a practical approach for improving diabetes management in DN patients.